Stock SYNACT SYNACT PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

All News SynAct Pharma AB

Equities

SYNACT

SE0008241491

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
8.425 SEK +1.44% Intraday chart for SynAct Pharma AB -5.34% -4.59%
Jul. 01 SynAct Pharma AB Initiates Filing Process for Phase 2b Advance Study with Resomelagon CI
May. 31 SynAct Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
BioStock: SynAct Pharma moves forward with filing process
AQ
SynAct initiates filing process for Phase 2b ADVANCE study with resomelagon
AQ
SynAct Pharma AB Initiates Filing Process for Phase 2b Advance Study with Resomelagon
CI
Bulletin from the annual general meeting 2024 in SynAct Pharma AB
AQ
SynAct Pharma publishes Q1 2024 interim results
AQ
SynAct Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
BioStock: SynAct Pharma's CEO provides an update
AQ
Change in number of shares and votes in SynAct Pharma AB
AQ
Notice of annual general meeting in SynAct Pharma AB
AQ
Bulletin from the extraordinary general meeting of SynAct Pharma AB
AQ
SynAct Pharma : Changes in SynAct Pharma's Nomination Committee ahead of the 2024 Annual General Meeting
PU
Changes in SynAct Pharma’s Nomination Committee ahead of the 2024 Annual General Meeting
AQ
Synact Pharma AB Announces Changes in Nomination Committee Ahead of the 2024 Annual General Meeting
CI
BioStock: Synact focuses on pushing forward rheumatoid arthritis project
AQ
Notice of extraordinary general meeting in SynAct Pharma AB
AQ
SynAct Pharma : has successfully completed the bookbuilding procedure - directed issues provide the company with a total of up to 49.2 MSEK.
PU
SynAct Pharma AB announces intention to carry out directed share issues in total of approximately 48 MSEK
AQ
SynAct Pharma publishes Annual Report 2023
AQ
SynAct Pharma AB (publ) ("SynAct") brings forward the publication of the annual report.
AQ
SynAct Pharma comments on ownership changes among senior executives
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SYNACT Stock
  4. News SynAct Pharma AB